Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Convertible Debt (2023 - 2025)

Serina Therapeutics (SER) has disclosed Convertible Debt for 2 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Convertible Debt changed N/A to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.9 million for FY2025, N/A changed from the prior year.
  • Convertible Debt hit $2.9 million in Q4 2025 for Serina Therapeutics, down from $3.0 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $3.0 million in Q4 2023 to a low of $2.9 million in Q4 2025.